Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed

Executive Summary

FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September

You may also be interested in...

Revising The Blueprint: FDA HQ Construction Nears Completion, But Some Planned Buildings On Hold

The Life Sciences-Biodefense lab complex would remain on schedule for completion in FY 2014, but communications and logistical buildings included in the campus master plan would be on hold.

Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says

CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.

FDA Office Of Pharmacoepidemiology Units Slated For September Move

Divisions from FDA's Office of Pharmacoepidemiology & Statistical Science (OPaSS) are expected to relocate to the agency's new White Oak, Md. campus in mid-September

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts